BION 📈 BB Biotech - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0038389992
BION: Biotech, Pharmaceuticals, Vaccines, Diagnostics, Therapies
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland. Web URL: https://www.bbbiotech.ch/en/bb-biotech/
Additional Sources for BION Stock
BION Stock Overview
| Market Cap in USD | 2,359m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception |
BION Stock Ratings
| Growth 5y | -57.4% |
| Fundamental | 5.55% |
| Dividend | 25.3% |
| Rel. Strength Industry | -1032 |
| Analysts | - |
| Fair Price Momentum | 33.35 CHF |
| Fair Price DCF | 68.98 CHF |
BION Dividends
| Dividend Yield 12m | 5.67% |
| Yield on Cost 5y | 3.92% |
| Annual Growth 5y | -14.12% |
| Payout Consistency | 81.1% |
BION Growth Ratios
| Growth Correlation 3m | 13.3% |
| Growth Correlation 12m | -84.1% |
| Growth Correlation 5y | -70.8% |
| CAGR 5y | -7.08% |
| CAGR/Mean DD 5y | -0.26 |
| Sharpe Ratio 12m | -0.76 |
| Alpha | -29.41 |
| Beta | 0.54 |
| Volatility | 20.81% |
| Current Volume | 60k |
| Average Volume 20d | 86.8k |
What is the price of BION stocks?
As of December 27, 2024, the stock is trading at CHF 35.30 with a total of 59,999 shares traded.
Over the past week, the price has changed by -3.95%, over one month by -4.98%, over three months by -3.42% and over the past year by -12.23%.
As of December 27, 2024, the stock is trading at CHF 35.30 with a total of 59,999 shares traded.
Over the past week, the price has changed by -3.95%, over one month by -4.98%, over three months by -3.42% and over the past year by -12.23%.
Is BB Biotech a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, BB Biotech is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 5.55 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BION as of December 2024 is 33.35. This means that BION is currently overvalued and has a potential downside of -5.52%.
Neither. Based on ValueRay Fundamental Analyses, BB Biotech is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 5.55 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BION as of December 2024 is 33.35. This means that BION is currently overvalued and has a potential downside of -5.52%.
Is BION a buy, sell or hold?
BB Biotech has no consensus analysts rating.
BB Biotech has no consensus analysts rating.
What are the forecast for BION stock price target?
According to ValueRays Forecast Model, BION BB Biotech will be worth about 36.3 in December 2025. The stock is currently trading at 35.30. This means that the stock has a potential upside of +2.83%.
According to ValueRays Forecast Model, BION BB Biotech will be worth about 36.3 in December 2025. The stock is currently trading at 35.30. This means that the stock has a potential upside of +2.83%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 55.9 | 58.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 36.3 | 2.8% |